Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone
Celldex Therapeutics dropped about 4% to $29.58 in premarket action Thursday, paring gains after the stock soared 24% to close at $30.82 the previous session.